SKLB-03220

• Target :

  Histone Methyltransferase

• Related Pathways :

  Chromatin/Epigenetic

• Purity :

  0.9702

• Bioactivity :

  SKLB-03220 is an orally bioavailable covalent inhibitor targeting the histone methyltransferase EZH2, an established oncology drug target involved in epigenetic regulation. SKLB-03220 is structurally based on the clinically approved EZH2 inhibitor tazemetostat and demonstrates the ability to abolish epigenetic H3K27me3 marks, thereby altering chromatin state and transcriptional activity. SKLB-03220 represents a potent small-molecule tool for cancer epigenetics research.

• Smiles :

  O=C(C=C)NC1=CC=C(C(=C1)C=2C=C(C(=O)NCC=3C(=O)NC(=CC3C)C)C(=C(C2)N(CC)C4CCOCC4)C)C

• Shipping Conditions :

  Cool pack

• Storage Temperature :

  -20°C

• CAS Number :

  2852050-29-2